Neuroendocrine tumors of the lung

Hidefumi Takei, Hisao Asamura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Neuroendocrine tumors of the lung embrace a spectrum from low-grade typical carcinoid, intermediate-grade atypical carcinoid, and high-grade categories of large cell neuroendocrine carcinoma(LCNEC) and small cell carcinoma(SCLC). Large cell neuroendocrine carcinoma is a newly recognized clinicopathologic entity as the fourth category of neuroendocrine tumors of the lung. The most common disagreements of pathological diagnosis fall between LCNEC and SCLC. The clinical characteristics and optimal treatments for patients with LCNEC are not presently defined well. The prognosis of LCNEC is suggested to be poorer than that of other non-small cell lung cancers in the recent studies. It is not clear how these patients should be treated. Further collaborative accumulation of clinicopathological data is strongly required.

Original languageEnglish
Pages (from-to)877-882
Number of pages6
JournalNippon rinsho. Japanese journal of clinical medicine
Volume62
Issue number5
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Neuroendocrine Tumors
Lung
Small Cell Carcinoma
Carcinoid Tumor
Non-Small Cell Lung Carcinoma

Cite this

Neuroendocrine tumors of the lung. / Takei, Hidefumi; Asamura, Hisao.

In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 62, No. 5, 2004, p. 877-882.

Research output: Contribution to journalArticle

@article{f64323347ce546f9849ab3a62b8ad871,
title = "Neuroendocrine tumors of the lung",
abstract = "Neuroendocrine tumors of the lung embrace a spectrum from low-grade typical carcinoid, intermediate-grade atypical carcinoid, and high-grade categories of large cell neuroendocrine carcinoma(LCNEC) and small cell carcinoma(SCLC). Large cell neuroendocrine carcinoma is a newly recognized clinicopathologic entity as the fourth category of neuroendocrine tumors of the lung. The most common disagreements of pathological diagnosis fall between LCNEC and SCLC. The clinical characteristics and optimal treatments for patients with LCNEC are not presently defined well. The prognosis of LCNEC is suggested to be poorer than that of other non-small cell lung cancers in the recent studies. It is not clear how these patients should be treated. Further collaborative accumulation of clinicopathological data is strongly required.",
author = "Hidefumi Takei and Hisao Asamura",
year = "2004",
language = "English",
volume = "62",
pages = "877--882",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "5",

}

TY - JOUR

T1 - Neuroendocrine tumors of the lung

AU - Takei, Hidefumi

AU - Asamura, Hisao

PY - 2004

Y1 - 2004

N2 - Neuroendocrine tumors of the lung embrace a spectrum from low-grade typical carcinoid, intermediate-grade atypical carcinoid, and high-grade categories of large cell neuroendocrine carcinoma(LCNEC) and small cell carcinoma(SCLC). Large cell neuroendocrine carcinoma is a newly recognized clinicopathologic entity as the fourth category of neuroendocrine tumors of the lung. The most common disagreements of pathological diagnosis fall between LCNEC and SCLC. The clinical characteristics and optimal treatments for patients with LCNEC are not presently defined well. The prognosis of LCNEC is suggested to be poorer than that of other non-small cell lung cancers in the recent studies. It is not clear how these patients should be treated. Further collaborative accumulation of clinicopathological data is strongly required.

AB - Neuroendocrine tumors of the lung embrace a spectrum from low-grade typical carcinoid, intermediate-grade atypical carcinoid, and high-grade categories of large cell neuroendocrine carcinoma(LCNEC) and small cell carcinoma(SCLC). Large cell neuroendocrine carcinoma is a newly recognized clinicopathologic entity as the fourth category of neuroendocrine tumors of the lung. The most common disagreements of pathological diagnosis fall between LCNEC and SCLC. The clinical characteristics and optimal treatments for patients with LCNEC are not presently defined well. The prognosis of LCNEC is suggested to be poorer than that of other non-small cell lung cancers in the recent studies. It is not clear how these patients should be treated. Further collaborative accumulation of clinicopathological data is strongly required.

UR - http://www.scopus.com/inward/record.url?scp=3142709986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142709986&partnerID=8YFLogxK

M3 - Article

C2 - 15148812

AN - SCOPUS:3142709986

VL - 62

SP - 877

EP - 882

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 5

ER -